UK Appeal Panel Tells NICE To Revisit Scenesse Rejection

An appeals panel has upheld some of the objections to NICE’s decision not to recommend Clinuvel’s Scenesse for NHS funding in England. The HTA body’s Highly Specialized Technologies committee will now have to reconsider its guidance in light of the panel’s conclusions. 

Think again!
NICE is to reconsider its recommendation on Clinuvel's Scenesse. • Source: Shutterstock

The health technology assessment body NICE is to look again at its decision not to recommend National Health Service funding in England for Clinuvel Pharmaceuticals Ltd.’s phototoxicity drug Scenesse, after an appeals panel upheld several objections by the company and patient organizations to NICE’s conclusions.

The panel said that NICE’s Highly Specialized Technologies committee would need to address a number of issues regarding the way...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Health Technology Assessment

More from Market Access